Topic: small cell lung cancer
The adjuvant use of I-O therapies could be a $29 billion market, currently led by BMS and Roche, according to Credit Suisse analysts.
BMS’s Opdivo failed a key small cell lung cancer trial in October, but the results may still be enough to protect the approval it already has.
Roche’s Tecentriq is closing in on a billion-dollar-plus lung cancer market that it can have all to itself.
Bristol-Myers Squibb’s Opdivo failed another small-cell lung cancer trial—and now, its Yervoy combination approval in the field could be in jeopardy.
BMS' Opdivo just took another hit to its lung cancer aspirations. The I-O blockbuster flunked a small cell lung cancer trial soon after Roche posted a first-line win.
Roche is looking to snag a $1 billion piece of the lung cancer market for its own, and it now has survival data to back up its bid.
Bristol-Myers Squibb may be trailing rival Merck in the non-small cell lung cancer market, but it has landed a niche of its own in the small cell arena.